WG
EIGR

Winton Group’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Winton Group’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-880
Closed -$271K – 1809
2019
Q3 		$271K Buy
+880
New +$286K ﹤0.01% 1311

Other funds holding EIGR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Winton Group's EIGR Position: Q4 2019 in Review

Winton Group sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2019, closing a stake of 880 shares — an estimated $271K sold.

Winton Group first reported a position in EIGR in Q3 2019 and held it in 1 quarter. The position peaked at $271K in Q3 2019. 91 funds tracked by Wall St. Rank hold EIGR as of Q4 2019.

  • Winton Group reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
  • Winton Group sold 880 Eiger BioPharmaceuticals, Inc. shares in Q4 2019, an estimated $271K.
  • Winton Group first reported a position in Eiger BioPharmaceuticals, Inc. in Q3 2019 and held it in 1 quarter.
  • Winton Group's Eiger BioPharmaceuticals, Inc. position peaked at $271K in Q3 2019.
  • 91 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2019.

Based on Winton Group's 13F filing for Q4 2019, filed 13 Feb 2020.